Companies › CellCentric
2 active drug programs in 3 registered trials: 1 Phase 2, 1 Phase 1, 1 Phase 3; Oncology; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Pomalidomide (CCS1477) CRL4(CRBN) E3 ubiquitin ligase inhibitor | CRBN, DDB1, CUL4A, RBX1 | Phase 3 | Multiple Myeloma Refractory | Nov 2029 |
| CCS1477 (Inobrodib) | – | Phase 2 | Multiple Myeloma Refractory; Haematological Malignancy | Mar 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04068597 | CCS1477 (Inobrodib) | Phase 1 | Haematological Malignancy | Oncology | Mar 2027 |
| NCT07772024 | Pomalidomide (CCS1477) | Phase 3 | Multiple Myeloma Refractory | Oncology | Nov 2029 |
| NCT07096778 | CCS1477 (Inobrodib) | Phase 2 | Multiple Myeloma Refractory | Oncology | Dec 2029 |
Bristol-Myers Squibb Roche Incyte Shandong New Time Pharmaceutical Beijing InnoCare Pharma Tech
IO Biotech iOnctura Toray Industries SynerGene Therapeutics Lyvgen Biopharma Holdings
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.